journal article·2019-01

Cationic Poly(Amino Acid) Vaccine Adjuvant for Promoting Both Cell‐Mediated and Humoral Immunity Against Influenza Virus

Jong‐Woo Lim, Woonsung Na, Hyun‐Ouk Kim, Minjoo Yeom, Geunseon Park, Aram Kang, Haejin Chun, Chaewon Park, Seungseok Oh, Van Phan Le, Hyoung Hwa Jeong, Daesub Song, Seungjoo Haam

Advanced Healthcare Materials· Volume 8· Issue 2
Publisher page

Abstract

Abstract Powerful adjuvants to augment vaccine efficacy with a less immunogenic vaccine system are in great demand. In this study, a novel squalene‐based cationic poly(amino acid) adjuvant (CASq) that elicits both cellular (Th1) and humoral (Th2) immune responses is developed. CASq is demonstrated to promote cellular uptake of viral antigen and stimulate macrophages, leading to active production of interleukin‐12. Furthermore, co‐administration of inactivated pdm H1N1 vaccine with CASq significantly increases the generation of antigen‐specific antibodies and T cell immune responses in mice, as well as resulting in complete prevention of disease symptoms and protection against lethal infection.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Immune Response and Inflammation · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical and Biomolecular Engineering Yonsei University Yonsei‐ro 50 Seoul 03722 Republic of Korea

College of Pharmacy Korea University Sejong‐ro Sejong 30019 Republic of Korea

Department of Microbiology and Infectious Diseases College of Veterinary Medicine Vietnam National University of Agriculture Hanoi 100000 Vietnam

Huvet Bio Inc. 127 Beobwon‐ro Seoul 05836 Republic of Korea

Funding

National Research Foundation of Korea · Ministry of Science, ICT and Future Planning

References (31)

Show source-provided references
1. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
2. 10.1038/nm.340910.1038/nm.3409 ↗
3. 10.1016/j.vaccine.2014.06.04310.1016/j.vaccine.2014.06.043 ↗
4. 10.1016/j.addr.2009.09.00510.1016/j.addr.2009.09.005 ↗
5. 10.1016/j.jim.2003.11.00210.1016/j.jim.2003.11.002 ↗
6. 10.1038/nbt.234410.1038/nbt.2344 ↗
7. 10.1016/j.vaccine.2013.11.06910.1016/j.vaccine.2013.11.069 ↗
8. 10.1038/nri348810.1038/nri3488 ↗
9. 10.1002/adfm.20160065010.1002/adfm.201600650 ↗
10. 10.1016/j.immuni.2016.02.00410.1016/j.immuni.2016.02.004 ↗
11. 10.1021/nn305466z10.1021/nn305466z ↗
12. 10.1002/adhm.20160075010.1002/adhm.201600750 ↗
13. 10.1016/j.jconrel.2017.04.02710.1016/j.jconrel.2017.04.027 ↗
14. 10.1039/c1nr10166h10.1039/c1nr10166h ↗
15. 10.1016/j.vaccine.2009.07.01210.1016/j.vaccine.2009.07.012 ↗
16. 10.1038/srep2450610.1038/srep24506 ↗
17. 10.1016/j.biomaterials.2012.09.06210.1016/j.biomaterials.2012.09.062 ↗
18. 10.1016/j.biomaterials.2010.07.05610.1016/j.biomaterials.2010.07.056 ↗
19. 10.1002/anie.20100507510.1002/anie.201005075 ↗
20. 10.1002/ange.20100507510.1002/ange.201005075 ↗
21. 10.1016/j.biomaterials.2015.03.00610.1016/j.biomaterials.2015.03.006 ↗
22. 10.1016/j.biomaterials.2013.02.00610.1016/j.biomaterials.2013.02.006 ↗
23. 10.1002/smll.20170081810.1002/smll.201700818 ↗
24. 10.1021/nn404055310.1021/nn4040553 ↗
25. 10.1038/ni.312310.1038/ni.3123 ↗
26. 10.1038/ni.203910.1038/ni.2039 ↗
27. 10.3390/ijms1103078910.3390/ijms11030789 ↗
28. 10.1016/j.cell.2007.10.04610.1016/j.cell.2007.10.046 ↗
29. 10.1186/s13567-016-0400-710.1186/s13567-016-0400-7 ↗
30. 10.1002/anie.20130288110.1002/anie.201302881 ↗
31. 10.1002/ange.20130288110.1002/ange.201302881 ↗